Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer
jRCT2031210415Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tarlatamab in neuroendocrine prostate cancer (NEPC) (2 arms), sponsored by Amgen. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs), Number of participants with treatment-related adverse events (TRAEs) and 1 more. Started Jun 2021; status: completed.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on jRCT2031210415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210415.